The total cost was $23.75 million and the licensed business had pre-acquisition revenues of approximately $14 million, according to Mar Cor, which is a subsidiary of Cantel Medical Corp.
"The Gambro heat-disinfection central system is a great enhancement to our water-for-dialysis portfolio,” said Curt Weitnauer, president of Mar Cor. “These new products will help us address two major trends in dialysis water offerings: hot water disinfection and single patient treatment. We'll be able to provide our dialysis clinic customers the broadest and most advanced array of water treatment alternatives from chemical to heat disinfection and single to multi-patient systems."
Mar Cor said will immediately commence sales and service of all Gambro water products, components, parts and consumables solely intended for the U.S. market.
The manufacturing of these products will be transitioned into Mar Cor's ISO 13485 Registered Medical Device manufacturing facility in Plymouth, Minn. Mar Cor will provide service and support to Gambro's installed base of over 1,200 clinics and hospitals in the United States. All U.S. employees aligned with Gambro's water business will be offered employment with Mar Cor, which will help provide a smooth transition for all Gambro customers.
"Building atop the success of our acquisition of GE Water & Process Technologies' dialysis water business and other Mar Cor regional acquisitions, we are continuing to execute our strategy of marrying cutting-edge products with our nationwide service network to fulfill the needs of our customers,” said Cantel's President and CEO, Andrew Krakauer. “Our Water Purification and Filtration segment will now be nearly $100 million in sales. I am very pleased and confident in the leadership of our Mar Cor group and anticipate both top and bottom-line synergies to result from this unique opportunity."
